CD8A and cancer: Overall, we demonstrate that in patients receiving cancer ICI therapy, worsening fatigue associates with expansion of cytotoxic effector CD8+ T cells and Th1-associated cytokines, implicating fatigue as a marker of immune activation in patients treated with ICIs.